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With stroke burden increasing, there remains a need to identify therapeutic options that ameliorate 
the acute insult. There is substantial evidence for a neuroprotective effect of marine-derived n-3 





To assess the effects of administration of marine-derived n-3 PUFAs on functional outcomes and 
dependence in people with stroke. 
 
Our secondary outcomes were vascular-related death, recurrent events, incidence of other type of 
stroke, adverse events, quality of life, and mood. 
 
Search methods 
We searched the Cochrane Stroke Group trials register, the Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE, Embase, CINAHL EBSCO, and Web of Science (SCI-EXPANDED, CPCI-S, 




We included randomized controlled trials (RCTs) comparing marine-derived n-3 PUFAs to placebo or 
open control in people with a history of stroke and/or transient ischemic attack. 
 
Data collection and analysis 
 
Two authors independently selected trials for inclusion, extracted data, and assessed risk of bias and 





We included 29 RCTs; nine of them provided outcome data (3339 participants). Only one study 
included participants with acute stroke (subarachnoid hemorrhage). Doses of marine-derived n-3 
PUFAs ranged from 400 to 3300 mg/day. Risk of bias was generally low or unclear, and the quality of 
the evidence ranged from low to very low. We divided the studies by short (up to three months) and 




One pilot study reported clinical outcome assessed with Glasgow Outcome Scale Extended (risk ratio 
(RR) of poor outcome 0.78, 95% confidence interval (CI) 0.36 to 1.68; 40 participants; very low 
quality evidence). Mood (assessed with GHQ-30, lower score better), was reported by one study and 
favored control (mean difference (MD) 1.41, 95% CI 0.07 to 2.75; 102 participants; low-quality 
evidence). 
 
We found no evidence of an effect of the intervention for vascular-related death, recurrent events, 





One small trial assessed functional outcome (52 participants; very low quality evidence) with Barthel 
Index (MD 7.09, 95% CI −5.16 to 19.34; higher score is better) and Rivermead Mobility Index (MD 
1.30, 95%CI −1.31 to 3.91; higher score is better). 
 
We found no evidence of an effect of the intervention for vascular-related death, recurrent events, 
mood and adverse events. Incidence of other type of stroke and quality of life were not reported. 
 
Implications for practice and research  
 
We are very uncertain of the effect of marine-derived n-3 PUFAs therapy on functional outcomes 
and dependence after stroke as there is insufficient high-quality evidence.  
 
More well-designed RCTs are needed, specifically in acute stroke, to determine the efficacy and 
safety of the intervention. Future studies might consider starting the intervention as early as 
possible after the event, as well as using standardized clinically-relevant outcome measures, such as 
the modified Rankin Scale. Optimal doses remain to be determined; delivery forms and mode of 
administration also need further consideration. 
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